TRX transgenic (TRX-Tg) mice, in which the human TRX gene is systemically overexpressed under the control of the β-actin promoter, and mice in which recombinant human TRX is systemically administrated are resistant to injury in various models of human diseases including viral pneumonia [14], acute lung injury [15,16], pancreatitis [17,18], myocarditis [19], chronic obstructive pulmonary disease (COPD) [20,21], indomethacin-induced gastric injury [22], and lipopolysaccharide-induced preterm delivery [23]. This evidence concerns the gene ACTB and chronic obstructive pulmonary disease.